Keywords: بواسیزوماب; Bevacizumab; Diabetic tractional retinal detachment; OCTA; Vitreous hemorrhage;
مقالات ISI بواسیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بواسیزوماب; Stereotactic body radiotherapy; Bevacizumab; Colorectal cancer; Liver metastases; CT perfusion;
Keywords: بواسیزوماب; Metastatic colorectal cancer; Bevacizumab; Primary tumor resection;
Keywords: بواسیزوماب; Brainstem; Glioma; Bevacizumab; VEGF; Malignant; Progression;
Keywords: بواسیزوماب; Glioblastoma; Neurosurgery; Neuro-oncology; Bevacizumab; Progressive glioblastoma;
Keywords: بواسیزوماب; Human serum albumin; Bevacizumab; Nanoparticles; Controlled release; Ocular delivery; Desolvation;
Keywords: بواسیزوماب; NSCLC; non-small cell lung cancer; RCTs; randomized controlled trials; OS; overall survival; PFS; progression free survival; ORR; objective response rate; AEs; adverse effects; HR; hazard ratio; RR; relative risk; CI; confidence intervals; FDA; Food and D
Keywords: بواسیزوماب; Metastatic colorectal cancer; First-line chemotherapy; Duration of treatment; Maintenance treatment; De-escalated treatment; Cetuximab; Bevacizumab;
Keywords: بواسیزوماب; PMH; past medical history; ROS; review of systems; WNL; within normal limits; C; cycle; BP; blood pressure; UTI; urinary tract infection; NIDDM; non-insulin-dependent diabetes mellitus; Advanced cervical cancer; Metastatic cervical cancer; Recurrent cervi
Keywords: بواسیزوماب; Bevacizumab; Brain tumor; Chemotherapy; Cognition; Corticosteroids; Fatigue; Mood; Seizure;
Keywords: بواسیزوماب; Astrocytoma; Oligodendroglioma; Anaplastic; IDH; 1p/19q codeletion; PCV; Temozolomide; Bevacizumab;
Keywords: بواسیزوماب; Cervix cancer; Neo-adjuvant chemotherapy, adjuvant chemotherapy; Concurrent chemo-radiation; Targeted therapy; Bevacizumab; Immune check point inhibitor;
Keywords: بواسیزوماب; Bevacizumab; PLGA nanoparticles; Cryoprotectant; Antiangiogenic therapy; Long-term stability;
Keywords: بواسیزوماب; Bioanalysis; Fluoroimmunoassay; Cancer immunotherapy; Therapeutic monoclonal antibodies; Bevacizumab; Cetuximab;
Keywords: بواسیزوماب; Renal cell carcinoma; Cabozantinib; Nivolumab; Ipilimumab; Bevacizumab; Atezolizumab;
Keywords: بواسیزوماب; AMD; age-related macular degeneration; BAB; blood-aqueous barrier; BC; Bruch's-choroid; Bev; bevacizumab; BRB; blood-retinal barrier; BSA; bovine serum albumin; Dex; dexamethasone; DSP; dexamethasone sodium phosphate; DMPC; dimyristoyl-phosphatidylcholine
Keywords: بواسیزوماب; Normalization window; Warburg effect; Tumor oxygenation; Bevacizumab; 92C05; 92C50;
Keywords: بواسیزوماب; Bevacizumab; Supramolecular interactions; Polymeric nanoparticles; Drug delivery platform; Mucoadhesion; Mucus penetration;
Keywords: بواسیزوماب; Bevacizumab; Carboplatin; Complete response; Paclitaxel; Spindle cell carcinoma;
Keywords: بواسیزوماب; Bevacizumab; Hypertension; Haplotype; WNK1; KLKB1; GRK4;
Keywords: بواسیزوماب; Anastrozole; Anti-estrogen; Bevacizumab; Endothelial; Estrogen; Factor; Growth; Inhibitor; Melasma; Modulator; Receptor; Selective; Tamoxifen; Therapy; Topical; Treatment; Vascular;
Keywords: بواسیزوماب; Lung cancer; Thoracic vascular; Tumor invasion; Bevacizumab; NSCLC; non-small cell lung cancer; CT; computed tomography; MRI; magnetic resonance imaging; PET; positron emission tomography; PA; pulmonary artery; PV; pulmonary vein; LA; left atrium;
Keywords: بواسیزوماب; Ovarian cancer; Bevacizumab; Biomarker;
Keywords: بواسیزوماب; TACE; Transarterial Chemoembolization; cTACE; conventional Transarterial Chemoembolization; HCC; hepatocellular carcinoma; EASL; European Association for the Study of the Liver Guidelines; qEASL; 3D quantitative European Association for the Study of the L
Keywords: بواسیزوماب; Antineoplastic agents/adverse effects; Angiogenesis inhibitors; Cardiotoxins; Vascular endothelial growth factor; Bevacizumab; Sorafenib; Sunitinib; Vandetanib; Aflibercept;
Keywords: بواسیزوماب; Avastin; Bevacizumab; Chemotherapy; Nasal septum; Perforation; Septal perforation; Sinonasal pathology; Ovarian cancer; Hereditary hemorrhagic telangiectasia;
Keywords: بواسیزوماب; Rechute platine sensible; Chirurgie; Chimiothérapie; Allergie; Bévacizumab; Olaparib; Platinum sensitive relapse; Surgery; Chemotherapy; Drug reaction; Bevacizumab; Olaparib;
Keywords: بواسیزوماب; CTD; connective tissue diseases; LC; lung cancer; SLE; systemic lupus erythematosus; PM/DM; polymyositis/dermatomyositis; SSc; systemic sclerosis; ILD; interstitial lung disease; IPF; idiopathic pulmonary fibrosis; AE; acute exacerbation; PS; performance
Keywords: بواسیزوماب; Colorectal; Cancer; Cost-effectiveness; Capecitabine; Bevacizumab;
Keywords: بواسیزوماب; Breast cancer; Primary metastatic disease; Breast surgery; Trastuzumab; Bevacizumab;
Keywords: بواسیزوماب; Bevacizumab; Breast cancer; Personalized medicine; Subgroup analysis; Multivariate statistical classification; Machine learning; FGF; fibroblast growth factor; FLT; fms-like tyrosine kinase; HER2; human epidermal growth factor receptor 2; MRST; in mean re
Keywords: بواسیزوماب; Antiangiogenic drugs; Glioblastoma; Bevacizumab; Chemotherapy;
Keywords: بواسیزوماب; Metastatic colorectal cancer; Primary tumour location; Sidedness; Prognostic biomarker; Predictive biomarker; Cetuximab; Panitumumab; Bevacizumab; Anti-EGFR; Anti-VEGF;
Keywords: بواسیزوماب; Retinopathy of prematurity (ROP); Vascular endothelial growth factor (VEGF); Bevacizumab; Prematurity; Aggressive posterior retinopathy of prematurity;
Keywords: بواسیزوماب; Recurrent malignant glioma; ATRX; Alpha thalassemia/mental retardation syndrome X-linked; Bev; Bevacizumab; CNS; Central nervous system; EGFR; Epidermal growth factor receptor; GBM; Glioblastoma multiforme; Gy; Gray; HRQoL; Health-related quality of life;
Keywords: بواسیزوماب; Breast cancer; fatigue; chronic fatigue; bevacizumab; C-reactive protein (CRP);
Keywords: بواسیزوماب; Colorectal liver metastases; Sinusoidal obstruction syndrome; Bevacizumab; Hepatotoxicity; Liver resection; Oxaliplatin;
Keywords: بواسیزوماب; Chemotherapy; Health-related quality of life; High-grade glioma; KPS; Recurrence therapy; Recurrent surgery; Re-radiation; Bev; Bevacizumab; CCNU; Lomustine; EORTC QLQ-BN20; European Organisation for Research and Treatment of Cancer Quality of Life Questi
Keywords: بواسیزوماب; Angiotensin; Bevacizumab; Chemotherapy; Microenvironment; Non-small-cell lung cancer;
Keywords: بواسیزوماب; Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab;
Keywords: بواسیزوماب; Bevacizumab; Trabecular meshwork; Schlemm's canal; Clearance; Intraocular pressure; Choroidal neovascularization; CNV; vascular endothelial growth factor; VEGF; age-related macular degeneration; AMD; intraocular pressure; IOP; trabecular meshwork; TM; Sch
Keywords: بواسیزوماب; Bevacizumab; glioblastoma; high grade glioma; immunotherapy; ipilimumab;
Keywords: بواسیزوماب; Bevacizumab; Recurrent ovarian cancer; Secondary cytoreductive surgery; Response to second-line chemotherapy
Keywords: بواسیزوماب; Ovarian cancer; Bevacizumab; Treatment preference; Discrete choice experiment; Trade-off question;
Keywords: بواسیزوماب; ADCC; antibody dependent cellular cytotoxicity; AUC; area under the concentration-time curve; CL; clearance; mAbs; monoclonal antibodies; M-M; Michaelis-Menten; PBS; phosphate-buffered saline; PK; pharmacokinetic; TMB; tetramethylbenzidine; TMDD; ta
Keywords: بواسیزوماب; Bevacizumab; Maintenance; SCLC; Target therapy; Thalidomide;
Keywords: بواسیزوماب; Metastatic breast cancer; Metastatic colorectal cancer; Trastuzumab; Bevacizumab; Anthracycline; Cyclophosphamide; Paclitaxel; Irinotecan; Fluorouracil; Leucovorin;
Keywords: بواسیزوماب; Proinflammatory cytokine; VEGF; Bevacizumab; Triamcinolone acetonide; Retinal laser photocoagulation;
Keywords: بواسیزوماب; Bevacizumab; Light-scattering; Validation; Aggregation kinetics; Stability;
Keywords: بواسیزوماب; bevacizumab; antibody; voltammetry; glassy carbon electrode; denaturing agents;